After a 4-week treatment, when compared with the control group, the tumor volume was reduced by 68.54 and 53.19%, respectively, in Group III (SG511-CCL5-ODD92) and Group II (NK-92), and Group III (SG511-CCL5-ODD92) showed more tumor repression than Group II (NK-92) (P<0.01). The gene discussed is CCL5; the disease is neoplasm.